The synopsis for this grant opportunity is detailed below, following
this paragraph. This synopsis contains all of the updates to this
document that have been posted as of
12/05/2012
. If
updates have been made to the opportunity synopsis, update information
is provided below the synopsis.
If you would like to receive notifications of changes to the grant
opportunity click
send
me change notification emails
.
The only thing you need to provide for this service is your email
address. No other information is requested.
Any inconsistency between the original printed document and the disk
or electronic document shall be resolved by giving precedence to the
printed document.
Document Type:
Grants Notice
Funding Opportunity Number:
PA-13-034
Opportunity Category:
Discretionary
Posted Date:
Dec 05, 2012
Creation Date:
Dec 05, 2012
Original Closing Date for Applications:
Jan 07, 2016
Current Closing Date for Applications:
Jan 07, 2016
Archive Date:
Feb 07, 2016
Funding Instrument Type:
Grant
Category of Funding Activity:
Food and Nutrition
Health
Category Explanation:
Expected Number of Awards:
Estimated Total Program Funding:
Award Ceiling:
Award Floor:
CFDA Number(s):
93.839
--
Blood Diseases and Resources Research
93.847
--
Diabetes, Digestive, and Kidney Diseases Extramural Research
Cost Sharing or Matching Requirement:
No
Eligible Applicants
State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility:
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Agency Name
National Institutes of Health
Description
This Funding Opportunity Announcement (FOA) issued by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health, encourages investigator-initiated R01 applications that propose hypothesis-driven research using erythroid cells. The aim of this program is to support research efforts towards a complete description of the molecular and cellular components of erythropoiesis and how these components contribute to erythropoiesis. Components include genes that are expressed (transcriptome) in erythroid cells, either during development or during differentiation, and the proteins (proteome) that are translated in erythroid cells, especially with post-translational modifications or subcellular localizations that are unique to erythroid cells. A long range goal of this program is to generate a concise description of erythropoiesis that unifies genetics, molecular processes and cytokine determinants in the erythroid lineages so that new therapeutics may be developed to measure and combat anemia.
